文献速递肾癌与肾肿瘤前列腺癌

在英国生物样本库中验证肺癌筛查项目内肾癌筛查的效果估计

Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank.
PubMed 文献 · Eur Urol Oncol · 2023-03-30

本研究利用英国生物样本库队列(n=442 865)评估约克郡肺癌筛查试验(YLST)资格标准用于筛选肾癌筛查人群的表现,并测量两种常用肺癌筛查资格模型(PLCO[m2012]和Liverpool-Lung-Project-v2)及联合YLST标准对肾癌的区分度。肺癌模型对肾癌的曲线下面积在0.60至0.68之间;在英国,预计四分之一(25%)的肾癌病例发生于符合肺癌筛查条件者中,每邀请200人参加肺癌筛查可检出1例肾癌。作者认为将肾癌筛查加入肺癌筛查可有效提高肾癌早期检出率,但多数肾癌不会被此方法发现,且该分析未涉及过度诊断等其他重要考量。

要点

  • 肺癌筛查资格模型对肾癌的区分度曲线下面积在0.60至0.68之间。
  • 英国预计25%的肾癌病例发生于符合肺癌筛查条件的人群中。
  • 每邀请200人参加肺癌筛查可检出1例肾癌。

核心结论

  • 将肾癌筛查加入肺癌筛查可能是提高肾癌早期检出率的有效策略,但多数肾癌不会被此方法发现。

研究设计与样本

  • 利用英国生物样本库队列(n=442 865)评估约克郡肺癌筛查试验(YLST)资格标准筛选肾癌筛查人群的表现,并测量PLCO[m2012]和Liverpool-Lung-Project-v2两种肺癌筛查资格模型及联合YLST标准对肾癌的区分度。

主要发现

  • 肺癌模型对肾癌的区分度曲线下面积在0.60至0.68之间。
  • 在英国,预计四分之一(25%)的肾癌病例发生于符合肺癌筛查条件者中。
  • 每邀请200人参加肺癌筛查可检出1例肾癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该分析未涉及过度诊断等其他关于肾癌筛查的重要考量。
  • 多数肾癌不会被此方法发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the absence of population-based screening, addition of screening for kidney cancer to lung cancer screening could provide an efficient and low-resource means to improve early detection. In this study, we used the UK Biobank cohort (n = 442 865) to determine the performance of the Yorkshire Lung Cancer Screening Trial (YLST) eligibility criteria for selecting individuals for kidney cancer screening. We measured the performance of two models widely used to determine eligibility for lung cancer screening (PLCO[m2012] and the Liverpool-Lung-Project-v2) and the performance of the combined YLST criteria. We found that the lung cancer models have discrimination (area under the receiver operating curve) between 0.60 and 0.68 for kidney cancer. In the UK, one in four cases (25%) of kidney cancer cases is expected to occur in those eligible for lung cancer screening, and one case of kidney cancer detected for every 200 people invited to lung cancer screening. These results suggest that adding kidney cancer screening to lung cancer screening would be an effective strategy to improve early detection rates of kidney cancer. However, most kidney cancers would not be picked up by this approach. This analysis does not address other important considerations about kidney cancer screening, such as overdiagnosis. PATIENT SUMMARY: It has been proposed that adding-on kidney cancer screening to lung cancer screening (both carried out by a computed tomography scan of the chest/abdomen) would be an easy and low-cost way of detecting cases of kidney cancer earlier, when these can be treated more easily. Lung cancer screening is usually targeted at people who are at a high risk (eg, older smokers); therefore, here we look at whether the same group of people are also at a high risk of kidney cancer. Our analysis shows that one in four people later diagnosed with kidney cancer are also at a high risk of lung cancer; hence, a combined screening programme could detect up to a quarter of kidney cancers.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Harrison H, Wood A, Pennells L, et al. Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank. Eur Urol Oncol. 2023. PMID: 37003861. doi:10.1016/j.euo.2023.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。